NASDAQ:AGIO

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$21.74

-0.24 (-1.09%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $21.07
▼
$21.94
50-Day Range: $21.74
▼
$30.93
52-Week Range: $16.75
▼
$34.76

Volume: 603,436 shs
Average Volume: 583,842 shs
Market Capitalization: $1.20 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.75

Institutional Ownership

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 73.6% Upside
$37.75 Price Target
Short Interest: Bearish
11.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.82
Based on 3 Articles This Week
Insider Trading: Selling Shares
$2.20 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.76) to ($6.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

627th out of 1,005 stocks

Pharmaceutical Preparations Industry

300th out of 486 stocks

3.4

Analyst's Opinion

Consensus Rating
Agios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.75, Agios Pharmaceuticals has a forecasted upside of 73.6% from its current price of $21.74.
Amount of Analyst Coverage
Agios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.08% of the float of Agios Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Agios Pharmaceuticals has recently increased by 1.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Agios Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Agios Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agios Pharmaceuticals has received a 73.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agios Pharmaceuticals is -0.87.

2.1

News and Social Media Coverage

News Sentiment
Agios Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Agios Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,204,382.00 in company stock.
Percentage Held by Insiders
Only 4.48% of the stock of Agios Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.76) to ($6.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agios Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agios Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Agios Pharmaceuticals has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

March 23, 2023 | marketwatch.com

From 2023 to 2031, Cholangiocarcinoma Pipeline Market Insight

March 18, 2023 | americanbankingnews.com

Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells $449,800.00 in Stock

March 26, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

March 15, 2023 | marketwatch.com

Cholangiocarcinoma Pipeline Market Industry Trends, Significant Growth and Forecast to 2028

March 14, 2023 | marketwatch.com

Cholangiocarcinoma Pipeline Market Evolution Segmentation and Insight of Trends 2023 to 2028

March 8, 2023 | finance.yahoo.com

TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels

February 28, 2023 | finance.yahoo.com

Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day

February 27, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Agios Pharma (AGIO)

March 26, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

February 25, 2023 | seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript

February 24, 2023 | msn.com

Agios Pharmaceuticals's Return On Capital Employed Insights

February 24, 2023 | finance.yahoo.com

Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss

February 24, 2023 | finance.yahoo.com

Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade

February 23, 2023 | finanznachrichten.de

Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023 | finance.yahoo.com

Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates

February 23, 2023 | msn.com

Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M

February 23, 2023 | finance.yahoo.com

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023 | thestreet.com

Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?

February 9, 2023 | marketwatch.com

Tibsovo Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2028

February 9, 2023 | marketwatch.com

Ivosidenib Market to Grow Significantly by Leading Players 2023 to 2028

February 2, 2023 | finance.yahoo.com

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

January 30, 2023 | marketwatch.com

Cholangiocarcinoma Pipeline Market 2023 : Trends, Industry Size, Share, Emerging Trends, Top Leading Players and Forecast 2028

January 15, 2023 | finance.yahoo.com

Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago

January 8, 2023 | finance.yahoo.com

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

January 7, 2023 | forbes.com

Agios Pharmaceuticals

January 3, 2023 | finance.yahoo.com

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

January 3, 2023 | finance.yahoo.com

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings: 11/03/2021
Today: 3/26/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGIO
CUSIP: N/A
CIK: 1439222
Web: www.agios.com
Phone: (617) 649-8600
Fax: N/A
Employees: 390
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.75
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $32.00
Forecasted Upside/Downside: +73.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-231,800,000.00
Net Margins: -1,627.82%
Pretax Margin: -1,627.82%
Return on Equity: -20.68%
Return on Assets: -18.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.30
Quick Ratio: 13.16

Sales & Book Value

Annual Sales: $14.24 million
Price / Sales: 84.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.03 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 55,280,000
Free Float: 52,808,000
Market Cap: $1.20 billion
Optionable: Optionable
Beta: 0.96

Key Executives

Brian M. Goff
Chief Executive Officer & Director

Cecilia Jones
Chief Financial Officer

Clive Patience
Chief Technical Operations Officer

Sarah Gheuens
Chief Medical Officer, Head-Research & Development

Charlie Newman
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price forecast for 2023?: 4 analysts have issued 1 year price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they expect the company's share price to reach $37.75 in the next year. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2023?: Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO shares have decreased by 22.6% and is now trading at $21.74.
View the best growth stocks for 2023 here.
When is Agios Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($1.48) EPS for the quarter, topping the consensus estimate of ($1.57) by $0.09. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 20.68% and a negative net margin of 1,627.82%. During the same period in the previous year, the business posted ($1.43) EPS.
What ETFs hold Agios Pharmaceuticals' stock?: ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Goldman Sachs Future Health Care Equity ETF (GDOC) and WisdomTree U.S. SmallCap Fund (EES).
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?: 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
What is Agios Pharmaceuticals' stock symbol?: Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
Who are Agios Pharmaceuticals' major shareholders?: Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (5.01%), Dimensional Fund Advisors LP (3.01%), First Trust Advisors LP (2.97%), Price T Rowe Associates Inc. MD (2.69%), ArrowMark Colorado Holdings LLC (2.62%) and Macquarie Group Ltd. (2.57%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends.
How do I buy shares of Agios Pharmaceuticals?: Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Agios Pharmaceuticals' stock price today?: One share of AGIO stock can currently be purchased for approximately $21.74.
How much money does Agios Pharmaceuticals make?: Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.20 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($4.24) on an earnings per share basis.
How many employees does Agios Pharmaceuticals have?: The company employs 390 workers across the globe.
How can I contact Agios Pharmaceuticals?: Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

Agios Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

AGIO Stock News Headlines

AGIO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AGIO Stock - Frequently Asked Questions

Overall MarketRank^™